Finasteride
- Generic Name
- Finasteride
- Brand Names
- Entadfi, Propecia, Proscar
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36N2O2
- CAS Number
- 98319-26-7
- Unique Ingredient Identifier
- 57GNO57U7G
- Background
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an ...
- Indication
Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. A combination product with tadalafil is also used...
- Associated Conditions
- Androgenetic Alopecia (AGA), Benign Prostatic Hyperplasia (BPH), Idiopathic Hirsutism, Symptomatic benign prostatic hyperplasia (BPH)
- Associated Therapies
- -
Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Ente Ospedaliero Ospedali Galliera
- Target Recruit Count
- 125
- Registration Number
- NCT06601205
- Locations
- 🇮🇹
Medical Oncology Ente Ospedaliero Ospedali Galliera, Genova, Italy
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Indonesia University
- Target Recruit Count
- 40
- Registration Number
- NCT05990400
- Locations
- 🇮🇩
University Indonesia, Jakarta, Other (Non U.s.), Indonesia
The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Benha University
- Target Recruit Count
- 60
- Registration Number
- NCT04848181
- Locations
- 🇪🇬
Benha University, Banhā, Qalyubia, Egypt
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT04288427
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2019-06-20
- Lead Sponsor
- Polichem S.A.
- Target Recruit Count
- 458
- Registration Number
- NCT03004469
- Locations
- 🇭🇺
Site #308, Satoraljaujhely, Hungary
🇩🇪Site #203, Dusseldorf, Germany
🇩🇪Site #204, Freiburg, Germany
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 169
- Registration Number
- NCT02781311
- Locations
- 🇺🇸
DeNova Research, Chicago, Illinois, United States
🇺🇸Cleveland Clinic, Dept of Dermatology, Cleveland, Ohio, United States
🇺🇸Heartland Research Associates, LLC, Wichita, Kansas, United States
Sleep Apnea in Elderly
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 100
- Registration Number
- NCT02703220
- Locations
- 🇺🇸
John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States
H-36731: Finasteride in Management of Elevated Red Blood Cells
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Baylor College of Medicine
- Registration Number
- NCT02548117
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Testosterone Plus Finasteride Treatment After Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 33
- Registration Number
- NCT02248701
- Locations
- 🇺🇸
North Florida/South Georgia Veterans Health System, Gainesville, FL, Gainesville, Florida, United States
🇺🇸James A. Haley Veterans' Hospital, Tampa, FL, Tampa, Florida, United States
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 403
- Registration Number
- NCT02244229
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.